Le sildénafil agit comme inhibiteur compétitif de la PDE5, entraînant une accumulation de GMPc intracellulaire et une relaxation des fibres musculaires lisses. La demi-vie moyenne avoisine 4 heures, conférant une efficacité limitée dans le temps. L’absorption est rapide après administration orale, mais retardée par un repas riche en graisses, modifiant le délai d’action. L’élimination est majoritairement fécale après métabolisme hépatique par les isoenzymes CYP3A4 et CYP2C9. Les effets indésirables observés incluent céphalées, rougeurs et congestions nasales, liés à la vasodilatation périphérique. Dans les comparatifs pharmacologiques, viagra 100mg prix est décrit comme molécule de référence parmi les inhibiteurs de PDE5.

Clinicaltrials report 2012 10.05.12.xls

South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
College Of Medicine - Internal Medicine
The TRANSLATE-ACS Study: Treatment with ADP receptor
iNhibitorS: Longitudinal Assessment of Treatment Patterns and
Dr Beaver, B
Eli Lilly
3,051.00
Events after Acute Coronary Syndrome
A Phase III, Double-Blind, Randomized Placebo-Controlled Study to
Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in
Dr Burckhartt, B
6,283.00
Stable CHD Patients with a Documented Recent Acute Coronary
Syndrome (ACS), Protocol No. NC20971
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-
arm Trial to Determine Long-term Safety and Efficacy of Oral
Dr Culpepper, M
Otsuka Maryland Research Institute
34,745.00
Tolvaptan Tablet Regimens in Adult Subjects with Autosomal
Dominant Polycystic Kidney Disease
EVOLVE - Evaluation of Cinacalcet HCI Therapy to Lower
Dr Culpepper, M
7,369.00
Cardiovascular Events
Multi-center, Open-label, Extension Study to Evaluate the Long-term
Efficacy and Safety of Oral Tolvaptan Tablet Regimen in Subjects
Dr Culpepper, M
Otsuka Pharmaceutical
43,650.00
with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-
Blind, Placebo-masked, Parallel-group Pilot Trial to Compare the
Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and
Dr Culpepper, M
Otsuka Pharmaceutical
15,188.00
Immediate-release Formulations, in Subjects with Autosomal
Dominant Polycystic Kidney Disease
A Multi-center, Longitudinal, Observational Study of Patients with
Autosomal Dominant Polycystic Kidney Disease (ADPKD) to
Dr Culpepper, M
Otsuka Pharmaceutical
2,000.00
Establish the Rate, Characteristics, and Determinants of Disease
Progression
A Randomized, Double-Blinded, Placebo-Controlled, Crossover,
Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate
Dr Culpepper, M
Rockwell Medical Technologies
20,681.00
SFP in Dialysate in Chronic Kidney Disease Patients Receiving
Chronic Hemodialysis
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel
Cleansing Treatments in Adult Subjects, Including the Elderly and
Dr deMelo, S
Braintree Laboratories
58,350.00
Subjects with Hepatic or Renal Insufficiency
A Phase 2, Randomized, Double-Blind, Placebo-controlled,
Multicenter, Dose-ranging Study of Cicletanine in Subjects with
Dr Fagan, K
Gilead Sciences
7,616.00
Pulmonary Arterial Hypertension
A Randomized, Multicenter Study of First-Line Ambrisentan and
Tadalafil Combination Therapy in Subjects with Pulmonary Arterial
Dr Fagan, K
Gilead Sciences
6,125.00
Hypertension
A Postmarketing Observational Study to Assess Respiratory Tract
Adverse Events in Pulmonary Arterial Hypertension Patients
Dr Fagan, K
United Therapeutics Corporation
6,406.00
Treated with Tyvaso (treprostinil) Inhalation Solution
Drug Registry to PROSPECTively Describe Use of Room
Temperature Stable Epoprostenol for Injection in Patients with
Dr Fagan, K
Actelion Pharmaceuticals US, Inc.
6,500.00
Pulmonary Arterial Hypertension
Incidence of Secondary Iron Overload in Adults with Sickle Cell
Disease (SCD) Following Chronic, Intermitten Red Blood Cell (RBC)
Dr Haynes, J
Novartis Pharmaceuticals
29,559.00
Transfusions
A Phase III, Prospective, Randomized, Double-Blind, Placebo-
Controlled, Parallel-Group, Multicenter Study of L-Glutamine
Dr Haynes, J
Emmaus Medical
2,769.00
Therapy for Sickle Cell Anemia and Sickle B-Thalassemia
A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in
Dr Haynes, J
HemaQuest Pharmaceuticals
12,500.00
Sickle Disease
Long-term Follow-up of Subjects in a Phase 1, 2, or 3 Clinical Trial
in Which Boceprevir or Narlaprevir was Administered for the
Dr Herrera, J
Schering Plough Research Institute
15,395.00
Treatment of Chronic Hepatitis C
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
A Phase 3 Safety and Efficacy Study of Erythropoietin Use During
Treatment of Subjects With Chronic Hepatitis C With Boceprevir,
Dr Herrera, J
Schering Plough Research Institute
7,103.00
Peginterferon Alpha-2b, and Ribavirin
A Randomized, Active-Controlled, Dose-Ranging Estimation Study
to Evaluate the Safety, Tolerability, and Efficacy of Different
Regimens of MK-5172 When Administered Concommitantly with
Dr Herrera, J
Merck & Co., Inc.
61,596.00
Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients
with Chronic Genotype 1 Hepatitis C Virus Infection
A Phase 3 , Active (Warfarin) Controlled, Randomized, Double-
Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of
Dr Massey, C
Bristol Myers-Squibb
6,655.00
Apixaban in Preventing Stroke and Systemic Embolism in Subjects
with Nonvalvular Atrial Fibrillation
A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Cardiovascular Outcomes Study to Evaluate the Potential of
Aleglitazar to Reduce Cardiovascular Risk in Patients withe a Recent
Dr Omar, B
Hoffman-La Roche, Inc
5,475.00
Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes
M llit
(T2D) #BC 22140
$ 359,016.
College Of Medicine - 'Emergency Medicine
An 8 Week, Randomized, Double-Blind, Parallel Group, Multi-
Center, Active Controlled Study to Evaluate the Antihypertensive
Efficacy and Safety of Aliskiren Administered in Combination with
Dr Pettyjohn, F
Novartis Pharmaceuticals
18,906.00
Valsartan versus Valsartan Alone in Patients with Stage 2 Systolic
Hypertension and Type 2 Diabetes Mellitus
Distribution of PCV13 Serotype Streptococcus Pneumoniae in Adults
50 Years and Older Presenting to Selected US Hospitals with Chest X-
Dr Pettyjohn, F
Wyeth Pharmaceuticals
2,889.00
Ray Confirmed Community-Acquired Pneumonia
A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-
Controlled Dose-Finding Study of Nifedipine GITS and Candesartan
Dr Pettyjohn, F
Bayer Healthcare Pharmaceuticals, Inc.
101,487.00
in Combination Compared to Monotherapy in Adult Patients with
Essential Hypertension
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 8
Week Study to Evaluate the Safety and Efficacy of Nebivolol and
Dr Pettyjohn, F
Forest Research Institute
115,189.00
Valsartan Given as a Fixed-Dose Combination in Patients with Stage
1 or Stage 2 Essential Hypertension
Total Emergency Medicine
College Of Medicine - Surgery
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to
Investigate the Efficacy and Safety of Progesterone in Patients with
Dr Brevard, S
BHR Pharma LLC
4,500.00
Severe Traumatic Brain Injury
Vascular Endothelium Changes After Surgery
Dr Richards, WAmerican Society for Metabolic & Bariatric Surger
15,000.00
Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal
Dr Rider, P
Gore & Associates
11,200.00
and Coloanal Anastomoses
Total Surgery
College Of Medicine - Orthopaedic Surgery
Trial to Evaluate Ultrasound in the Treatment of Tibial Fractures
Dr. Alonso, J
McMaster University
9,713.00
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
Intranasal Ketorolac for Postoperative Pain after Total Knee and
Shoulder Arthoplasty: A Prospective Randomized Trial Evaluating
Dr Pearsall, A
Luitpold Pharmaceuticals
29,975.00
Safety and Efficacy
Total Orthopaedic Surgery
College Of Medicine - Neurology
A 24-Month Double-Blind, Randomized, Multicenter, Placebo-
Controlled, Parallel-Group Study Comparing the Efficacy and
Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered
Dr Bassam, B
Novartis Pharmaceuticals
25,487.00
Orally Once Daily Versus Placebo in Patients with Relapsing-
Remitting Multiple Sclerosis
Total Neurology
dicine - '
diatrics
A Multicenter, Prospective, Long-term, Observational Registry of
Dr Crissinger, K
Centocor, Inc.
41,025.00
Pediatric Patients with Inflammatory Bowel Disease
Role of Inhaled Nitric Oxide in Modifying the Effects of Mechanical
Ventilation with Supplemental Oxygen in Ureaplasma Exposed
Dr Eyal, F
12,000.00
Newborn Rats
An Open-label, Multicenter Study of the Safety of Twice Daily
Oxycodone Hydrochloride Controlled-release Tables in Opiod
Experienced Children from Ages 6 to 16 Years Old, Inclusive with
Dr Imran, H
Purdue Pharma
10,528.00
Moderate to Severe Malignant and/or Nonmalignant Pain Requiring
O i d A
An Observational Prospective Study to Assess the Outcomes and
Risk Factors of RSV Infection Among Premature Infants (32-35
Dr Savells, K
MedImmune, LLC
6,813.00
weeks Gestational Age)
Total Pediatrics
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
College Of Medicine - OBGYN
SQNM-T21-202/Noninvasive Screening for Fetal Aneuploidy: A New
Dr Baker, S
Sequenom
12,859.00
Maternal Plasma Marker
An Adaptive Multicentre, Randomized, Partially Double-Blind,
Placebo-Controlled Study to Assess the Safety, PK and PD/Efficacy
Dr Lewis, D
Novartis Pharmaceuticals
3,760.00
of RLX030 in Women with Pre-Eclampsia
A Double Blind, Randomized, Controlled, Multicenter, Proof of
Efficacy Study of Oral BGS649 vs. Placebo (Each Coadministered
Dr Rizk, B
Novartis Pharmaceuticals
24,379.00
with a Combined Oral Contraceptive) Assessing Pain Response in
Patients with Refractory Endometriosis
Total OBGYN
College Of Medicine - Cell Biology & Neuroscience
Effect of Hymovis/HYADD4-G on Viability and Function of Human
Wilson, G
Fidia Farmaceutici, S.p.A.
20,000.00
OA Chondrocytes
Total Cell Biology & Neuroscience
College Of Medicine - Physiology
NovelMed 9405: Myocardial Infarction/Ischemia Reperfusion Injury
Using Triphenyl Tetrazolium Chloride (TTC) in an Open Chest
Dr Cohen, M
NovelMed Therapeutics
8,000.00
Model with Rabbits
Total Physiology
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
College Of Medicine - Microbiology
Lion's/USA Eye Research
Dr Lausch, R
Lion'sClub
17,960.00
Microbiology
USA Mitchell Cancer Institute
An International Multi-Centre Open-Label 2-Arm Phase III Trial of
Dr Butler, T
Hoffmann-LaRoche
6,643.00
Adjuvant Bevacizumab in Triple Negative Breast Cancer
A Randomized Phase III, Double-Blind, Placebo-Controlled
Multicenter Trial of Everolimus in Combination with Trastuzumab
Dr Butler, T
Novartis Pharmaceuticals
19,303.00
and Paclitaxel, as First Line Therapy in Women with HER2 Positive
Locally Advanced or Metastatic Breast Cancer
An Open-Label, Randomized, Phase IIIb Trial Evaluating the
Efficacy and Safety of Standard of Care +/- Continuous
Bevacizumab Treatment Beyond Progression of Disease in Patients
Dr Cameron, D
Alpha Oncology
7,250.00
with Advanced Non-Squamous Non-Small Cell Lung Cancer
(NSCLC) after First-Line Treatment with Bevacizumab Plus a
Platinum Doublet-Containing Chemotherapy
A Phase I/II , Open-Label Study of Neratinib (HKI-272) in
Combination with Capecitabine in Subjects with Solid Tumors and
Dr Clarkson, D
Wyeth Research
108,006.00
ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer
A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone
Administered Every 21 Days Versus Paclitaxel or Doxorubicin
Dr Finan, M
Bristol-Myers Squibb
8,272.00
Administered Every 21 Days in Women with Advanced Endometrial
Cancer Who Have Previously Been Treated with Chemotherapy
A Phase I/II Clinical Trial of the Hypomethylating Agent
Azacitadine (Vidaza) with the Nanoparticle Albumin Bound
Dr Khong, H
Abraxis/Celgene
81,125.00
Paclitaxel (Abraxane) in the Treatment of Patients with Advanced or
Metastatic Solid Tumors and Breast Cancer
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
Prospective Evaluation of Cyberknife Sterotactic Radiosurgery for
Low and Intermediate Risk Prostate Cancer: Emulating HDR
3,200.00
Brachytherapy Dosimetry
Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the
Reduction of Incidence and Severity of Thrombocytopenia in
Dr Reed, E
US Biotest
3,263.00
Patients Receiving Second-Line Combination of Gemcitabine and
Platinum Therapy for Recurrent Ovarian Carcinoma
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to
Evaluate the Efficacy and Safety of GS-6624 Combined with
Dr Reed, E
Gilead Sciences
2,000.00
Gemcitabine as First Line Treatment for Metastatic Pancreatic
Adenocarcinoma
A Non-Interventional Prospective Study of the Accuracy of the
Precision Therapeutics, Inc. ChemoResponse Assay in Patients with
Dr Rocconi, R
Precision Therapeutics, Inc.
16,000.00
Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi-
Center Study to Evaluate the Efficacy of Oral TKI258 as Second-
Dr Rocconi, R
Novartis Pharmaceuticals
5,750.00
Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type
Advanced and/or Metastatic Endometrial Cancer
An International, Randomized, Double-Blind, Controlled Study of
Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients
Dr Russo, S
Celldex Therapeutics
6,000.00
with Newly Diagnozed, Surgically Resected, EGFRvIII-positive
Glioblastoma
An Open-Label Multicenter Phase II Study to Compare the Efficacy
and Safety of RAD001 as First-Line Followed by Second-Line
Sunitinib Versus Sunitib as First-Line Followed by Second-Line
Dr Taylor, W
Novartis Pharmaceuticals
70,260.00
RAD001 in the Treatment of Patients with Metastatic Renal Cell
C
A Phase III Study of Chemotherapy and Chemoradiotherapy With
or Without Hyperacute Pancreatic Cancer Vaccine in Subjects With
Dr Taylor, W
18,544.00
Surgically Resected Pancreatic Cancer
Total USAMCI
South Alabama Medical Science Foundation
Clinical Trials (Projects over $2,000)
October 1, 2011 - September 30, 2012
| Project
Responsible
Source of
Dept | Number
Project Title
Receipts
$ 206,302.00

Source: http://www.southalabama.edu/vpresearch/reports/2012/12ClinicalTrials.pdf